Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Bruges – page 14

209 clinical trials in Bruges, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bruges at a glance
209
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

209 trials in Bruges

Open in trial search

Bladder cancer

Not recruiting

Study Comparing TAR-200 and Chemotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer After BCG Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Janssen Cilag International

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Chronic lymphocytic leukaemia

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab, Venetoclax, and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Genmab A/S

Heart failure with reduced ejection fraction

Not recruiting

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tovinontrine
  • Sponsor:Cardurion Pharmaceuticals Inc.

Axial spondyloarthritis

Not recruiting

Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Diffuse large B-cell lymphoma

Not recruiting

Study on Acalabrutinib with Drug Combination for Patients 75 and Older with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Mantle cell lymphoma

Not recruiting

Study on Ibrutinib, CD20 Ab and Venetoclax for Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:LYSARC

Study of Imetelstat in Patients with Low or Intermediate Risk Myelodysplastic Syndromes (MDS) Refractory to Erythropoiesis-Stimulating Agents

Not recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Imetelstat Sodium
  • Sponsor:Geron Corp.

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Heart failure with preserved ejection fraction

Not recruiting

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Preserved Ejection Fraction

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tovinontrine
  • Sponsor:Cardurion Pharmaceuticals Inc.

Bladder transitional cell carcinoma

Not recruiting

Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Herpes simplex

Not recruiting

Study on Pritelivir for Treating Acyclovir-Resistant Herpes Simplex Virus in Immunocompromised Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Cidofovir
  • Sponsor:AiCuris Anti-infective Cures AG

Other cities in France

The busiest research cities in the country

All 379 cities in France

Clinical research in Bruges

What the registry says about research in the country

01 Pain Management Research

Studies focusing on innovative approaches to manage post-operative pain in patients undergoing shoulder arthroscopy, evaluating the effectiveness of various pain management protocols and their impact on morphine consumption.

  • Arthroscopic Surgery Pain Control
  • Post-operative Pain Management
  • Analgesic Requirements Assessment

Research aims to optimize pain control strategies following minimally invasive shoulder procedures.

02 Neurology & Headache Treatment

Innovative research exploring the therapeutic potential of ketamine and magnesium sulfate combination for treating resistant chronic cluster headaches, offering hope for patients who don't respond to conventional treatments.

  • Chronic Cluster Headache Management
  • Drug Repurposing Studies
  • Treatment-Resistant Pain Conditions

This research represents a novel approach to addressing severe neurological pain conditions through medication repurposing.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.